• 80.2% of patients were using a catheter at hemodialysis initiation in 2013, which has changed little since 2005.
Introduction
For the first time, the USRDS devotes an entire chapter of this year's ADR to the critically important topic of vascular access for hemodialysis patients, previously covered in Chapter 3: Clinical Indicators and Preventive Care. In addition, monthly CROWNWeb data on type of vascular access in use is being reported for the first time in the ADR for all dialysis patients in the United States; not just those with Medicare claims. For details on CROWNWeb, see the ESRD Analytical Methods chapter. Clinical practice guidelines recommend an autogenous arteriovenous (AV) fistula as the preferred vascular access for hemodialysis (National Kidney Foundation, 2006) . A recent systematic review of 62 cohort studies with a total of 586,337 patients evaluated the association between type of vascular access and risk of mortality, infection, and major cardiovascular events. While recognizing the risk of selection bias inherent in observational studies, it concluded that central venous catheters (hereafter, catheter[s] ) were associated with the highest risk of death, infection, and cardiovascular events, compared with other types of vascular access, and that patients who had a usable AV fistula were associated with the lowest risk (Ravani et al., 2013) .
The international Dialysis Outcomes and Practice Patterns Study (DOPPS) brought much needed attention to vascular access practices around the world and highlighted the fact that U.S. dialysis practices with respect to vascular access lagged behind other industrialized countries of the world (Pisoni et al., 2002; Goodkin et al., 2010; Robinson et al., 2010) . In large part, these international comparisons served as impetus for implementation by the Health Care Financing Administration (HCFA) (now the Centers for Medicare & Medicaid [CMS] ), which was later renamed the Fistula First Breakthrough Initiative (FFBI). A steady increase in AV fistula placement efforts followed in the United States over the next decade, such that the proportion of prevalent hemodialysis patients with AV fistula rose from 32% in 2003 to 62% by 2013.
A robust debate continues as to whether an AV fistula should remain the access of first choice in every dialysis patient. Although an AV fistula continues to be considered the optimal type of vascular access in many patients owing to its potential for durability, lower risk of infection and intervention to ensure patency, the focus has shifted somewhat toward creating the most appropriate access for the individual patient, based upon the clinical situation, patient characteristics, life expectancy, patient preference, and other factors. Whether this approach will indeed prove superior can only be determined by more robust prospective studies/clinical trials, which will most likely be challenging to conduct.
A landmark clinical trial where maturation of an AV fistula was a secondary outcome, revealed the high prevalence of failure of newly place fistulae ever coming to use (Dember et al., 2008) . This topic remains of high interest to the nephrology community (Riella, et al., 2013) and led to the NIDDK funded Fistula Maturation Study (Dember et al., 2014) designed to study this phenomenon further. Between primary surgical failures and maturation failures, 30-50% of AV fistula placements in the United States are unsuccessful (Table 4 .9). The many potential factors underlying this phenomenon need to be rigorously evaluated so that primary surgical success rates and subsequent optimal maturation of the AV fistula, could be ensured. In this regard, greater emphasis on AV fistula placement during surgical training may need to be prioritized (Saran et al., 2008; Goodkin et al., 2010) in the United States.
Interventional nephrology has gained prominence in the United States over the last decade or so, introducing a new class of specialists involved with vascular access procedures to a field previously dominated primarily by surgeons and interventional radiologists trained in vascular access procedures. The impact of this phenomenon on patient outcomes has yet to be systematically studied.
All of the above considerations make it imperative to comprehensively and carefully track vascular access placements and related practices and outcomes. In addition to patient characteristics, other factors such as technological advances, improved surgical and medical treatments, use of specific medications, payment reform and bundling, and improved predialysis care can impact vascular access practice patterns and outcomes. Despite the emphasis on improving AV fistula success rates, at the time of initial dialysis 80% of patients are using a catheter. Improvements in pre-dialysis care during the critical transition period to ESRD may be the key to future improvements in this suboptimal practice pattern.
This chapter describes patterns of vascular access use among incident and prevalent dialysis patients by patient characteristics and geographic region over the last decade. In addition, we explore variation in timeto-first-use of AV fistula after placement as a surrogate of 'AV fistula maturation' across the country.
Analytical Methods
See the ESRD Analytical Methods chapter for an explanation of analytical methods used to generate the figures and tables in this chapter. to nearly 63% and placement increasing from 38% to 66% of patients, respectively. In contrast, AV graft use has decreased from 40% to 19% over the same time period. Catheter use has also declined, albeit not as dramatically, decreasing from 27% to 19%. In 2013, only 8% of prevalent hemodialysis patients had been using a catheter for >90 days. 
Vascular Access Use at Initiation of Hemodialysis

Vascular Access Use Among Prevalent Hemodialysis Patients
Change in Type of Vascular Access During the First Year of Dialysis
Figure 4.7 shows cross-sectional data from both the CMS Medical Evidence form (CMS 2728) (for vascular access information at initiation) and CROWNWeb (for follow-up data with respect to vascular access in use at 3, 6, 9 months and 1 year). At 90 days, most hemodialysis patients were still using a catheter, highlighting the importance of ongoing efforts to improve pre-dialysis access planning. The percentage of patients using an AV fistula exclusively at the end of 1 year on dialysis was 65%, up from 17% at initiation of hemodialysis. The proportion of patients with an AV graft for vascular access was 3% at initiation, and 15% at 1 year. Thus, at 1 year, 80% of patients were using either an AV fistula or AV graft without the presence of a catheter. Tables 4.3 through 4.5 show cross-sectional distributions of vascular access use at several time points during the first year of hemodialysis therapy, stratified by age, race, and gender. Catheter use is most common at initiation and at the end of one year in the 0-21 year old age group for reasons discussed above (higher transplant rates, anatomical challenges). AV graft use is higher in the 75+ age group both at initiation and at the end of 1 year. At 1 year, catheter use of approximately 20% is seen in all age groups, except the 0-21 year old cohort, indicating barriers still remain in establishing surgical access, even after 1 year. Black patients have the highest proportion of AV graft in use, both at initiation and at 1 year. At one year, 19.8% of Black patients had an AV graft in use compared to 13.5% of Asians and 12.2% of whites. Females have a higher proportion of AV graft use and males a higher proportion of AV fistula use both at initiation and at one year. Catheter use was highest in patients of other/unknown race and females at 1 year. For most adult patient age groups, over 60% higher fistula prevalence is achieved by one year on hemodialysis. At one year, the highest proportions of AV fistula were seen among males, those of Native American or Asian race, and the lowest AV fistula proportion was observed among African Americans.
Programs such as "Fistula First" and "Fistula First Catheter Last" were created to inform and educate the medical community on the higher morbidity, mortality, and costs associated with catheter use, while encouraging greater AV fistula use. Although AV fistula use has increased greatly in prevalent patients, improvement in AV fistula use at initiation continues to lag behind. Many reasons can be postulated for these trends, such as access to primary and/or nephrology care, disparities in health-care access, difficulty in AV fistula maturation in certain patient groups, such as the elderly diabetic or those with limited transportation or financial incentives, and the wide variety of health care providers with differing expertise in creating AV fistula for dialysis patients.
The following figures and tables examine associations between clinical and patient characteristics and successful surgical access use (AV fistula as well as AV fistula/AV graft use) at initiation of hemodialysis. Table 4 .6 examines patient characteristics as well as factors such as length of pre-ESRD care and CMS geographic regions (http://www.cms.gov/About-CMS/ Agency-Information/RegionalOffices/RegionalMap. html). Asians have the highest odds of successful AV fistula use at hemodialysis initiation, while both Asians and Blacks have the highest odds of a surgical access (AV fistula or AV graft) in use at hemodialysis initiation, with females less likely to be using an AV fistula/AV graft at initiation. Region 10 (Northwest) displays the highest odds of patients using an AV fistula at initiation as well as higher odds of AV fistula or AV graft use at hemodialysis initiation. Patients with ESRD secondary to diabetes are less likely to use an AV fistula or AV graft at hemodialysis initiation compared with patients for whom the primary cause of ESRD was not diabetes. 
Fistula Maturation
Timely fistula maturation is an area of central interest for the dialysis community. While AV fistula utilization among prevalent hemodialysis patients has improved (Figure 4 .5), the proportion of patients using a dialysis catheter at incidence of ESRD remains stubbornly high (Figure 4 .1). Limiting catheter exposure time is critical, as prolonged catheter use is often associated with bacteremia, sepsis, thrombosis and central stenoses (Morsy et al., 1998) , which limits future access success, as well as poor long-term outcomes . "Observational data indicate catheter use is associated with higher mortality risk, compared to other access types, potentially through the greater risk for sepsis and as a source of inflammation due to the 'foreign body' in the bloodstream effect, biofilm formation and other mechanisms, which may cause persistent adverse outcomes even after catheter removal" (Foley et al., JASN 2004) . While AV grafts are ready for use sooner and more reliably, their long-term primary and assisted primary patency are not as good and they are associated with a higher frequency of other complications that can significantly impact mortality and morbidity, including dialysis access-associated ischemia (also known as "dialysis hypoperfusion ischemic syndrome" and "steal syndrome") and infections (Churchill et al., 1992; Stevenson, 2002; Ravani, 2013) , adding significant risk with this choice of conduit. These complications can also have a significant impact on quality of life as well. Furthermore, the premature use of an AV graft may limit access options in the future (National Kidney Foundation, 2006)-a significant concern for those with longer life expectancy. At the present time, it is currently unclear as to at what point considerations related to prolonged AV fistula maturation time, and the associated catheter exposure, warrant prioritizing placement of AV graft instead, although conversion from a catheter to permanent access of either type is beneficial (Bradbury et al., 2009 ).
In an effort to better understand which patients experience longer maturation times, data on prevalent hemodialysis patients was examined, as these patients are more likely to experience use of their AV fistula as soon as it is reasonable to do so. Fistula placement was identified through inpatient, outpatient and physician/supplier Medicare claims using the following ICD-9 procedure codes: 36818, 36819, 36820, 36821 and 36825. Subsequent first use of the placed fistula was determined by finding evidence of fistula use in CROWNWeb through the end of 2014. If the fistula was indicated as being used in CROWNWeb following its placement (and prior to any subsequent fistula placements), the fistula was considered to have successfully matured for use. If CROWNWeb did not indicate the fistula was used following placement, the fistula was assumed to have failed to mature. In order to be included in the analyses patients were required to have vascular access use data in CROWNWeb following the fistula placement. Time to maturation was determined using the date of fistula placement and the date of first use in CROWNWeb, given that the exact time of 'fistula maturity' is currently not determinable from CROWNWeb. The percentage of fistula placements that failed was calculated as the number of failed placements over the total number of placements in 2013 among patients with vascular access use data in CROWNWeb. Patients that died following the fistula placement were included in the analysis. 
